Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kevin Platt

Physician Assistant Texarkana, TX Physician Assistant

NPI 1861520777 CMS profile 10911105

5002 Cowhorn Creek Rd, Texarkana, TX 75503

Open in the dashboard

General payments

$10,280

469 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Platt of Texarkana, TX is reported in the CMS Open Payments database as having received $10,280 across 469 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,255 145
2024 General $2,511 110
2023 General $2,641 119
2022 General $1,322 71
2021 General $552 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Platt
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kevin Platt were reported at $3,255. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kevin Platt Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $552 $132 $37–$438 $132
2022 $1,322 $155 $48–$522 $149
2023 $2,641 $167 $52–$557 $160
2024 $2,511 $178 $55–$600 $164
2025 $3,255 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,334 86 payments
  2. Inspire Medical Systems, Inc. $1,006 22 payments
  3. AstraZeneca Pharmaceuticals LP $909 47 payments
  4. Actelion Pharmaceuticals US, Inc. $844 31 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $828 35 payments
  6. Insmed, Inc. $657 36 payments
  7. Harmony Biosciences LLC $636 35 payments
  8. United Therapeutics Corporation $509 16 payments
  9. Avadel CNS Pharmaceuticals, LLC $479 12 payments
  10. Jazz Pharmaceuticals Inc. $316 12 payments
  11. Other $2,763 137 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,595 460 payments
  2. Education $486 8 payments
  3. Consulting Fee $200 1 payment
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,075 65 payments
  2. INSPIRE $850 21 payments
  3. Arikayce $586 30 payments
  4. UPTRAVI $550 15 payments
  5. OPSUMIT $519 22 payments
  6. LUMRYZ $479 12 payments
  7. FASENRA $470 21 payments
  8. OFEV Respiratory $340 13 payments
  9. OFEV Respiratory $319 13 payments
  10. BREZTRI $309 14 payments
  11. Other $5,545 280 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,538

Median for Physician Assistant: 241

Drug cost

$916,343

Median for Physician Assistant: $4,110

Branded share of claims

70.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 413 $398,331
Opsumit Macitentan Brand 12 $154,392
Xolair Omalizumab Brand 26 $86,941
Dupixent Pen Dupilumab Brand 21 $78,038
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 64 $40,038
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 43 $33,450
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 31 $26,895
Breo Ellipta Fluticasone/Vilanterol Brand 41 $23,039
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 15 $12,087
Tadalafil Generic 12 $10,619

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$58,969

Medicare's payments for the services billed

Medicare patients

512

Average age 75

Services billed

1,008

289 women, 223 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
COPD 47%
Ischemic heart disease 42%
Diabetes 36%
Chronic kidney disease 35%
Heart failure 33%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $237
$237 — —
WAKIX
  • Harmony Biosciences LLC $236
$236 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $229
$229 413 —
Arikayce
  • Insmed, Inc. $191
$191 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $181
$181 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

469 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record